european end-to-end CDMO company, pharma services
  • About us
    • History
    • Leaderships
    • Team
    • EU grants
    • Requests for Proposal
    • Sustainability – ESG
    • Bussines strategy
    • Quality policy
    • Virtual Tour
  • Services
    • Drug Substance Manufacturing
    • Fill & Finish
    • Gene to Vial: End-to-End Development
    • Process Development
    • Analytics 
    • Cell Line Development & Banking
  • Science Hub
    • Science News
    • Resources
  • News & Events
    • Press releases
    • Events
    • Content to download
  • Investors
    • Corporate documents
    • Shareholders and shares
    • Periodic reports
    • Current reports
    • Sustainability reports
    • Corporate governance at Mabion
    • Financial data
    • For Investors
    • Calendar
  • Contact us
    • Contact form
    • Contact for investors
    • Contact for media
    • Careers
  • EN
    • PL
  • Science News
  • Resources

Resources

Topic
All Analytics Antibody-drug conjugates Bioanalytics Biologics Biosimilars Biostatistics Cancer Cell culture Clinical trials Contamination Drug development Drug product Drug substance EMA FDA GMP Mabion Manufacturing Microbiology Partnership Proteins Regulatory Vaccines Veterinary biologics
Type
All Poster
latest trends in the prevention and treatment of cervical cancer

Latest trends in the prevention and treatment of cervical cancer

Cancer, Vaccines
EU Pharma Law Reform

Revolution in the EU pharmaceutical legislation ahead

EMA, Regulatory
Veterinary Monoclonal Antibodies

Development and regulation of veterinary monoclonals

Biologics, Drug development, Regulatory, Veterinary biologics
optimal CHO cell culture upstream process

Metabolite and nutrient analysis as crucial components for optimal CHO cell culture upstream process

Cell culture, Drug substance, Manufacturing
quantitation of monoclonal antibodies in serum - new technologies ECL, Gyrolab, and LC-MS/MS vs gold standard ELISA

Quantitation of monoclonal antibodies in serum: new technologies ECL, Gyrolab, and LC-MS/MS vs gold standard ELISA

Bioanalytics
Immunogenicity Impact on Efficacy and Safety of Biosimilars

Impact of immunogenicity on efficacy and safety of biosimilars – importance of ADA and nAb testing during the clinical development

Biologics, Drug product
Previous 1 … 10 11 12 Next

Contact

Find out how we may support your business.

bd@mabion.eu

Mabion

gen. Mariana Langiewicza 60
95-050 Konstantynów Łódzki
Poland

+48 42 207 78 90

    Mabion
    • Privacy policy
    • Services
    • Investors
    • News&Events
    • Contact us

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Page Sitemap.

    Powered by

    Veneo